PL3676285T3 - Szczepionka do stosowania w profilaktyce i/lub leczeniu choroby - Google Patents

Szczepionka do stosowania w profilaktyce i/lub leczeniu choroby

Info

Publication number
PL3676285T3
PL3676285T3 PL18762507.4T PL18762507T PL3676285T3 PL 3676285 T3 PL3676285 T3 PL 3676285T3 PL 18762507 T PL18762507 T PL 18762507T PL 3676285 T3 PL3676285 T3 PL 3676285T3
Authority
PL
Poland
Prior art keywords
prophylaxis
vaccine
disease
treatment
Prior art date
Application number
PL18762507.4T
Other languages
English (en)
Inventor
Peter Holst
Christian Thirion
Lasse NEUKIRCH
Original Assignee
Inprother Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inprother Aps filed Critical Inprother Aps
Publication of PL3676285T3 publication Critical patent/PL3676285T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
PL18762507.4T 2017-09-01 2018-08-30 Szczepionka do stosowania w profilaktyce i/lub leczeniu choroby PL3676285T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201770659 2017-09-01
PCT/EP2018/073404 WO2019043127A1 (en) 2017-09-01 2018-08-30 VACCINE FOR USE IN PROPHYLAXIS AND / OR TREATMENT OF DISEASE

Publications (1)

Publication Number Publication Date
PL3676285T3 true PL3676285T3 (pl) 2026-03-23

Family

ID=65526240

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18762507.4T PL3676285T3 (pl) 2017-09-01 2018-08-30 Szczepionka do stosowania w profilaktyce i/lub leczeniu choroby

Country Status (16)

Country Link
US (7) US11351247B2 (pl)
EP (4) EP4450516A3 (pl)
JP (3) JP7277466B2 (pl)
KR (1) KR20210050558A (pl)
CN (2) CN111630060B (pl)
AU (1) AU2018322831B2 (pl)
BR (1) BR112021003644A2 (pl)
CA (1) CA3074088A1 (pl)
DK (1) DK3676285T3 (pl)
EA (1) EA202090548A1 (pl)
ES (2) ES3058702T3 (pl)
FI (1) FI3676285T3 (pl)
HR (2) HRP20260041T1 (pl)
PL (1) PL3676285T3 (pl)
SI (1) SI3676285T1 (pl)
WO (2) WO2019043127A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351247B2 (en) 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
EP3852813A4 (en) 2018-09-18 2022-06-22 VNV Newco Inc. ARC-BASED CAPSIDS AND THEIR USES
US20210403907A1 (en) 2018-09-18 2021-12-30 Vnv Newco Inc. Arc-based capsids and uses thereof
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
BR112022009798A2 (pt) * 2019-11-20 2022-10-18 Bavarian Nordic As Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
CN112103353B (zh) * 2020-08-21 2023-07-18 中国地质大学（北京） 一种基于磷硒化锰(MnPSe3)场效应晶体管结构的光电探测器
AU2021342576A1 (en) * 2020-09-21 2023-04-06 University Of Georgia Research Foundation, Inc. PIV5-based covid-19 vaccine
WO2023039243A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
WO2024219994A1 (ru) * 2023-04-16 2024-10-24 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор на основе аденовируса человека 19 серотипа и способ его применения
WO2024218400A1 (en) * 2023-04-21 2024-10-24 Inprother Aps Improved expression of surface-displayed antigens
JP2026524442A (ja) * 2023-06-27 2026-07-22 インプラザー エー・ペー・エス ベータレトロウイルスＧａｇを含むキメラＶＬＰ形成ポリペプチド
WO2025002587A1 (en) * 2023-06-27 2025-01-02 Inprother Aps Chimeric vlp forming polypeptides comprising beta-retroviral gag
CN118561966B (zh) * 2024-05-20 2025-07-11 浙江大学 人内源性逆转录病毒包膜蛋白突变体、截短体及其用途
US12698309B2 (en) 2024-08-01 2026-08-04 Twilight Bioscience, Inc. HERV-K (HML-2) Env analog fusion proteins for antigen specific immunotherapy and methods of use
WO2026030596A1 (en) * 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use
CN119751661B (zh) * 2024-12-16 2026-07-17 浙江大学 抗herv-k102-su鼠源抗体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
CA2373352A1 (en) * 1999-07-02 2001-01-11 Onyx Pharmaceuticals, Inc. Adenoviral vectors for treating disease
CA2454879A1 (en) * 2001-08-15 2003-02-27 The Regents Of The University Of California Retrovirus isolated from mantle histiocytes in mantle cell lymphoma
AU2005229411B2 (en) 2004-03-30 2010-11-18 Centre National De La Recherche Scientifique Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins
EP2402447A1 (en) * 2005-03-30 2012-01-04 Viroxis Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
WO2007107156A2 (en) 2006-03-17 2007-09-27 Aarhus Universitet Chimeric viral envelopes
CA2658393A1 (en) * 2006-07-21 2008-01-24 The Regents Of The University Of California Human endogenous retrovirus polypeptide compositions and methods of use thereof
CA2735278A1 (en) 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine
US8920812B2 (en) * 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
WO2013026452A1 (en) 2011-08-23 2013-02-28 Skau Aps Method for removing immunosuppresive properties of hiv envelope glycoproteins
WO2013050048A2 (en) 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses
WO2013059426A1 (en) * 2011-10-21 2013-04-25 The Regents Of The University Of California Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof
EP2788372B1 (en) * 2011-12-07 2019-07-10 Viroxis S.A.S. Mutated lentiviral env proteins and their use as drugs
US9624510B2 (en) * 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
CA2912354C (en) 2013-06-07 2023-01-24 Viroxis S.A.S. Mutated non-primate lentiviral env proteins and their use as drugs
CA2999792A1 (en) * 2015-10-01 2017-04-06 Magdalena Janina LASKA Use of human derived immunosuppressive proteins and peptides as medicaments
EP3641804A1 (en) * 2017-06-22 2020-04-29 Institut Gustave Roussy Human endogenous retroviral protein
US11351247B2 (en) * 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease

Also Published As

Publication number Publication date
SI3676285T1 (sl) 2026-04-30
CA3074088A1 (en) 2019-03-07
BR112021003644A2 (pt) 2021-05-18
EP3676285B1 (en) 2025-11-05
EP3844178A1 (en) 2021-07-07
WO2020043908A1 (en) 2020-03-05
JP2020531053A (ja) 2020-11-05
EA202090548A1 (ru) 2020-06-23
DK3676285T3 (da) 2026-01-19
CN111630060A (zh) 2020-09-04
US11351247B2 (en) 2022-06-07
CN113056477B (zh) 2026-03-17
JP2025172855A (ja) 2025-11-26
US12390522B2 (en) 2025-08-19
JP7277466B2 (ja) 2023-05-19
US20220387580A1 (en) 2022-12-08
EP3844178B1 (en) 2025-08-20
WO2019043127A1 (en) 2019-03-07
ES3041285T3 (en) 2025-11-11
EP3844178C0 (en) 2025-08-20
KR20210050558A (ko) 2021-05-07
HRP20251176T1 (hr) 2025-12-19
ES3058702T3 (en) 2026-03-12
WO2019043127A9 (en) 2020-06-18
US20200330586A1 (en) 2020-10-22
AU2018322831A9 (en) 2020-07-23
EP4450516A2 (en) 2024-10-23
US12023377B2 (en) 2024-07-02
CN113056477A (zh) 2021-06-29
US20230181716A1 (en) 2023-06-15
EP4667485A3 (en) 2026-02-18
JP2023100875A (ja) 2023-07-19
US12263214B2 (en) 2025-04-01
US11883487B2 (en) 2024-01-30
EP4667485A2 (en) 2025-12-24
US20220347291A1 (en) 2022-11-03
US20250186579A1 (en) 2025-06-12
AU2018322831B2 (en) 2023-04-27
US20260077031A1 (en) 2026-03-19
US20240148860A1 (en) 2024-05-09
HRP20260041T1 (hr) 2026-04-10
CN111630060B (zh) 2024-01-23
AU2018322831A1 (en) 2020-03-12
EP3676285A1 (en) 2020-07-08
JP7735344B2 (ja) 2025-09-08
EP4450516A3 (en) 2025-01-22
FI3676285T3 (fi) 2025-12-18

Similar Documents

Publication Publication Date Title
SI3676285T1 (sl) Cepivo za uporabo pri profilaksi in/ali zdravljenju bolezni
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
SMT202500469T1 (it) Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla
IL251351A0 (en) Preparations for use in the treatment and prevention of surgical infections
ZA201704726B (en) Peptides and their use in the treatment of skin
GB2538923B (en) A therapeutic agent for use in the treatment of infections
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
IL264403A (en) Vortioxetine analogue and use and preparation thereof
GB2561945B (en) Tissue stain and use thereof
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL273863A (en) Hemorrhoid treatment device
GB201522329D0 (en) Use of adjuvants for the prevention and/or treatment of autoimmune diseases
PL3166660T3 (pl) Substancje i sposoby do zastosowania w profilaktyce i/lub leczeniu choroby Huntingtona
IL251407B (en) A multivalent compound for the treatment and prevention of brain damage
SG11201701618SA (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
EP3262060A4 (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
GB201410869D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
GB201710410D0 (en) Inorganic polyphosphate formulations for use in the treatment of alzheimer disease
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201712742D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases